| Replication competent molecular clones of HIV-1 expressing Renilla luciferase facilitate the analysis of antibody inhibition in PBMC TG Edmonds, H Ding, X Yuan, Q Wei, KS Smith, JA Conway, L Wieczorek, ... Virology 408 (1), 1-13, 2010 | 215 | 2010 |
| SARS-CoV-2 ferritin nanoparticle vaccines elicit broad SARS coronavirus immunogenicity MG Joyce, WH Chen, RS Sankhala, A Hajduczki, PV Thomas, M Choe, ... Cell reports 37 (12), 2021 | 124 | 2021 |
| Cross-clade neutralization patterns among HIV-1 strains from the six major clades of the pandemic evaluated and compared in two different models BK Brown, L Wieczorek, E Sanders-Buell, AR Borges, ML Robb, DL Birx, ... Virology 375 (2), 529-538, 2008 | 118 | 2008 |
| Neutralizing antibodies induced by liposomal HIV-1 glycoprotein 41 peptide simultaneously bind to both the 2F5 or 4E10 epitope and lipid epitopes GR Matyas, L Wieczorek, Z Beck, C Ochsenbauer-Jambor, JC Kappes, ... Aids 23 (16), 2069-2077, 2009 | 99 | 2009 |
| Human erythrocytes selectively bind and enrich infectious HIV-1 virions Z Beck, BK Brown, L Wieczorek, KK Peachman, GR Matyas, VR Polonis, ... PloS one 4 (12), e8297, 2009 | 70 | 2009 |
| Safety and immunogenicity of Ad26 and MVA vaccines in acutely treated HIV and effect on viral rebound after antiretroviral therapy interruption DJ Colby, M Sarnecki, DH Barouch, S Tipsuk, DJ Stieh, E Kroon, ... Nature Medicine 26 (4), 498-501, 2020 | 56 | 2020 |
| Foliar phenolic glycosides from Populus fremontii, Populus angustifolia, and their hybrids B Rehill, A Clauss, L Wieczorek, T Whitham, R Lindroth Biochemical Systematics and Ecology 33 (2), 125-131, 2005 | 56 | 2005 |
| Phase I study of safety and immunogenicity of an Escherichia coli-derived recombinant protective antigen (rPA) vaccine to prevent anthrax in adults BK Brown, J Cox, A Gillis, TC VanCott, M Marovich, M Milazzo, ... PLoS One 5 (11), e13849, 2010 | 48 | 2010 |
| A SARS-CoV-2 spike ferritin nanoparticle vaccine protects hamsters against Alpha and Beta virus variant challenge KMG Wuertz, EK Barkei, WH Chen, EJ Martinez, I Lakhal-Naouar, ... npj Vaccines 6 (1), 129, 2021 | 46 | 2021 |
| Late boosting of the RV144 regimen with AIDSVAX B/E and ALVAC-HIV in HIV-uninfected Thai volunteers: a double-blind, randomised controlled trial P Pitisuttithum, S Nitayaphan, S Chariyalertsak, J Kaewkungwal, ... The lancet HIV 7 (4), e238-e248, 2020 | 43 | 2020 |
| Multivalent dendrimeric compounds containing carbohydrates expressed on immune cells inhibit infection by primary isolates of HIV-1 AR Borges, L Wieczorek, B Johnson, AJ Benesi, BK Brown, RD Kensinger, ... Virology 408 (1), 80-88, 2010 | 43 | 2010 |
| Designing a soluble near full-length HIV-1 gp41 trimer G Gao, L Wieczorek, KK Peachman, VR Polonis, CR Alving, M Rao, ... Journal of Biological Chemistry 288 (1), 234-246, 2013 | 40 | 2013 |
| Broad and potent cellular and humoral immune responses after a second late HIV-modified vaccinia virus ankara vaccination in HIV-DNA-primed and HIV-modified vaccinia virus … C Nilsson, K Godoy-Ramirez, B Hejdeman, A Bråve, L Gudmundsdotter, ... AIDS research and human retroviruses 30 (3), 299-311, 2014 | 39 | 2014 |
| Low-dose in vivo protection and neutralization across SARS-CoV-2 variants by monoclonal antibody combinations V Dussupt, RS Sankhala, L Mendez-Rivera, SM Townsley, F Schmidt, ... Nature Immunology 22 (12), 1503-1514, 2021 | 38 | 2021 |
| Adjuvanted HIV-1 vaccine promotes antibody-dependent phagocytic responses and protects against heterologous SHIV challenge K Om, D Paquin-Proulx, M Montero, K Peachman, X Shen, L Wieczorek, ... PLoS pathogens 16 (9), e1008764, 2020 | 38 | 2020 |
| Comparable antigenicity and immunogenicity of oligomeric forms of a novel, acute HIV-1 subtype C gp145 envelope for use in preclinical and clinical vaccine research L Wieczorek, SJ Krebs, V Kalyanaraman, S Whitney, S Tovanabutra, ... Journal of virology 89 (15), 7478-7493, 2015 | 37 | 2015 |
| Detection of HIV-1 neutralizing antibodies in a human CD4+/CXCR4+/CCR5+ T-lymphoblastoid cell assay system RJ McLinden, CC LaBranche, AL Chenine, VR Polonis, MA Eller, ... PloS one 8 (11), e77756, 2013 | 36 | 2013 |
| Safety and immunogenicity of PENNVAX-G DNA prime administered by Biojector 2000 or CELLECTRA electroporation device with modified vaccinia Ankara-CMDR boost JA Ake, A Schuetz, P Pegu, L Wieczorek, MA Eller, H Kibuuka, F Sawe, ... The Journal of infectious diseases 216 (9), 1080-1090, 2017 | 28 | 2017 |
| The Catholic University of America AM Butts | 28* | 2014 |
| The role of natural killer (NK) cells and NK cell receptor polymorphisms in the assessment of HIV-1 neutralization BK Brown, L Wieczorek, G Kijak, K Lombardi, J Currier, M Wesberry, ... PLoS One 7 (4), e29454, 2012 | 23 | 2012 |
